IL142375A0 - Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent - Google Patents

Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent

Info

Publication number
IL142375A0
IL142375A0 IL14237599A IL14237599A IL142375A0 IL 142375 A0 IL142375 A0 IL 142375A0 IL 14237599 A IL14237599 A IL 14237599A IL 14237599 A IL14237599 A IL 14237599A IL 142375 A0 IL142375 A0 IL 142375A0
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
active agent
sustained release
pharmaceutically active
release pharmaceutical
Prior art date
Application number
IL14237599A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22627919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL142375(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL142375A0 publication Critical patent/IL142375A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14237599A 1998-10-14 1999-10-12 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent IL142375A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17249198A 1998-10-14 1998-10-14
PCT/EP1999/007627 WO2000021525A2 (en) 1998-10-14 1999-10-12 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent

Publications (1)

Publication Number Publication Date
IL142375A0 true IL142375A0 (en) 2002-03-10

Family

ID=22627919

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14237599A IL142375A0 (en) 1998-10-14 1999-10-12 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
IL142375A IL142375A (en) 1998-10-14 2001-04-02 A pharmaceutical preparation with a controlled release and a method for releasing a pharmacologically active substance

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL142375A IL142375A (en) 1998-10-14 2001-04-02 A pharmaceutical preparation with a controlled release and a method for releasing a pharmacologically active substance

Country Status (30)

Country Link
EP (1) EP1121116B1 (enExample)
JP (2) JP2002527388A (enExample)
KR (1) KR100517090B1 (enExample)
CN (1) CN1196481C (enExample)
AR (2) AR020780A1 (enExample)
AT (1) ATE382345T1 (enExample)
AU (1) AU765475B2 (enExample)
BR (1) BR9911648A (enExample)
CA (1) CA2346868C (enExample)
CO (1) CO5140079A1 (enExample)
CY (1) CY1107874T1 (enExample)
DE (1) DE69937891T2 (enExample)
DK (1) DK1121116T3 (enExample)
ES (1) ES2297936T3 (enExample)
HK (1) HK1040920B (enExample)
HU (1) HUP0104268A3 (enExample)
ID (1) ID29350A (enExample)
IL (2) IL142375A0 (enExample)
MY (1) MY121105A (enExample)
NO (1) NO327285B1 (enExample)
NZ (1) NZ511010A (enExample)
PE (1) PE20001110A1 (enExample)
PL (1) PL198850B1 (enExample)
PT (1) PT1121116E (enExample)
RU (1) RU2259826C2 (enExample)
SK (2) SK286596B6 (enExample)
TR (1) TR200101088T2 (enExample)
TW (1) TW577738B (enExample)
WO (1) WO2000021525A2 (enExample)
ZA (1) ZA200103001B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
ATE418979T2 (de) 2000-06-09 2009-01-15 Lek Pharmaceuticals Stabilisiertes arzneimittel und arzneizubereitung
DK1345595T3 (da) * 2000-09-29 2007-09-10 Solvay Pharm Bv Ionstyrke-uafhængig farmaceutisk formulering med depotfrigivelse
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US20060039974A1 (en) * 2002-09-11 2006-02-23 Takeda Pharmaceutical Company Limited Sustained release preparation
JP2007523664A (ja) * 2003-04-23 2007-08-23 フェリング ベスローテン フェンノートシャップ 医薬組成物用サシェ
US8987322B2 (en) 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
EP1940391A4 (en) * 2005-08-05 2010-01-20 Orbus Pharma Inc STABILIZED PHARMACEUTICAL COMPOSITIONS WITH EXTENDED RELEASE WITH AN HMG COA REDUCTASE INHIBITOR
BRPI0708191A2 (pt) * 2006-02-24 2012-05-29 Teva Pharma " composições farmacêuticas de fluvastatina sódica "
RU2342144C1 (ru) * 2007-04-05 2008-12-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтический состав, обладающий противосудорожным и психотропным действием
RU2356532C2 (ru) * 2007-06-01 2009-05-27 Открытое Акционерное Общество "Отечественные Лекарства" Фармацевтическая композиция проксодолола с контролируемым высвобождением
CN102805739B (zh) * 2012-04-10 2013-08-14 宋芸 氟伐他汀钠缓释包衣滴丸及其制备方法
BR112015016322A8 (pt) * 2013-01-09 2018-01-23 Edgemont Pharmaceuticals Llc formulações de liberação controlada de lorazepam
CN106344535B (zh) * 2016-08-29 2019-09-20 济南康和医药科技有限公司 一种氟伐他汀钠微孔渗透泵控释片及其制备方法
EP3720434A4 (en) 2017-12-05 2021-09-01 Sunovion Pharmaceuticals Inc. NON-RACEMIC MIXTURES AND THEIR USES
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
CN112955139B (zh) 2018-09-25 2025-04-18 庞塞迪利昂健康特定活动公司 用于制备α-酮戊二酸钙的方法
MX2021014774A (es) 2019-06-04 2022-02-03 Sunovion Pharmaceuticals Inc Formulaciones de liberacion modificada y usos de las mismas.
TWI869410B (zh) * 2019-06-10 2025-01-11 愛爾蘭商龐賽德萊昂健康公司 α－酮戊二酸鹽之持續釋放組合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
EP0465096A1 (en) * 1990-06-26 1992-01-08 Merck & Co. Inc. Plasma cholesterol level lowering composition
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release
AU706628B2 (en) * 1995-07-03 1999-06-17 Sankyo Company Limited Treatment of arteriosclerosis and xanthoma
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
SI0814782T1 (en) * 1995-12-22 2003-04-30 Kowa Company, Ltd. Pharmaceutical composition stabilized with a basic agent
SE9603667D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
ATE382345T1 (de) 2008-01-15
CY1107874T1 (el) 2013-06-19
RU2259826C2 (ru) 2005-09-10
AR069281A2 (es) 2010-01-13
ES2297936T3 (es) 2008-05-01
CN1196481C (zh) 2005-04-13
NO20011695D0 (no) 2001-04-04
AU765475B2 (en) 2003-09-18
PL198850B1 (pl) 2008-07-31
EP1121116A2 (en) 2001-08-08
JP2002527388A (ja) 2002-08-27
CN1328454A (zh) 2001-12-26
MY121105A (en) 2005-12-30
IL142375A (en) 2012-01-31
WO2000021525A3 (en) 2000-08-10
HK1040920B (zh) 2005-07-29
NZ511010A (en) 2003-10-31
DE69937891T2 (de) 2008-12-11
EP1121116B1 (en) 2008-01-02
HUP0104268A3 (en) 2002-06-28
NO20011695L (no) 2001-05-30
CA2346868C (en) 2008-09-09
AU6090999A (en) 2000-05-01
CO5140079A1 (es) 2002-03-22
BR9911648A (pt) 2001-03-20
DE69937891D1 (de) 2008-02-14
TW577738B (en) 2004-03-01
KR100517090B1 (ko) 2005-09-27
NO327285B1 (no) 2009-06-02
WO2000021525A2 (en) 2000-04-20
PL348109A1 (en) 2002-05-06
TR200101088T2 (tr) 2001-10-22
AR020780A1 (es) 2002-05-29
HK1040920A1 (en) 2002-06-28
JP4938383B2 (ja) 2012-05-23
HUP0104268A2 (hu) 2002-04-29
JP2006298945A (ja) 2006-11-02
DK1121116T3 (da) 2008-05-13
PT1121116E (pt) 2008-03-12
KR20010080156A (ko) 2001-08-22
SK286595B6 (sk) 2009-01-07
CA2346868A1 (en) 2000-04-20
ID29350A (id) 2001-08-23
SK286596B6 (sk) 2009-01-07
PE20001110A1 (es) 2000-11-01
ZA200103001B (en) 2002-07-11
SK5092001A3 (en) 2001-09-11

Similar Documents

Publication Publication Date Title
IL142375A0 (en) Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
IL137445A0 (en) Pharmaceutically active compounds and methods of use thereof
IL148168A0 (en) Pharmaceutical composition of nateglinide and another antidiabetic agent
AU2001263264A1 (en) Tablets and methods for modified release of hydrophilic and other active agents
PL342162A1 (en) Galenic form for oral administration of either immediate or prolonged drug release containing an absorption enhancing agent and application of such absorption enhancing agent
PL347634A1 (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
EP1337249A4 (en) COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE COMPOUNDS
IL141155A0 (en) Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
ZA964735B (en) Compositions and methods for topical administration of pharmaceutically active agents
EP1171117A4 (en) LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS
PL336296A1 (en) Composition of retarded active substance release and method of obtaining them
HUP0100900A3 (en) Pharmaceutically active morpholinol and medicaments containing them
PL337867A1 (en) Oral preparation of controllable opioidic analgesic agent release
AU6406299A (en) Methods and apparatus for improved administration of pharmaceutically active compounds
EP1115396A4 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS, AND METHODS OF USE THEREOF
PL344564A1 (en) Matrix tablet enabling prolonged release of trimethiazidine after oral administration and method of making such tablet
HUP0202654A3 (en) Pharmaceutical compositions of fibrinolytic agent and process for preparation thereof
PL337868A1 (en) Oral preparation of controllable analgesic agent release
GB2343117B (en) Benzimidazole pharmaceutical composition and process of preparation
IL139512A0 (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloaxacin or its pharmaceutically suitable salts or hydrates
PL339349A1 (en) Therapeutic agent preparation of controllable active substance release
IL126892A0 (en) Pharmaceutical compositions for the sustained release of insoluble active principles
IL136142A0 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
GB9904485D0 (en) Method for protecting and/or controlled release of active ingredient
PL350054A1 (en) Sustained release salts of pharmaceutically active peptides and their production